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INCREASED RISK OF CERVICAL DYSPLASIA IN LONG TERM SURVIVORS
OF ALLOGENEIC STEM CELL TRANSPLANTATION – IMPLICATIONS FOR
SCREENING AND HPV VACCINATION
Savani, B.N.1,2, Shenoy, A.1, Stratton, P.3, Filie, A.4, Kozanas, E.1,
Chauvet, D.1, Donohue, T.1, Le, Q.1, Childs, R.W.1, Goodman, S.2,
Barrett, A.J.1. 1National Institutes of Health, Bethesda, MD; 2Veterans
AffairsMedical Center and Vanderbilt University Medical Center, Nash-
ville, TN; 3National Institutes of Health, Bethesda, MD; 4National In-
stitutes of Health, Bethesda, MD.
Cervical, skin and head-neck cancer are most common secondary
solid cancers in long-term survivors after allogeneic stem cell trans-
plantation (allo-SCT). Although these cancers are linked to human
papillomavirus (HPV) infection, the relationship betweenHPV and
cancers after allo-SCT is not defined. Furthermore, Pap smear
screening after SCT is not practiced routinely. We carried out
a cross-sectional study of 92 patients receiving allo-SCT for hema-
tological malignancies, enrolled at a minimumof 3 years post-trans-
plantation between 04/2005–06/2007 in an IRB-approved long-
term evaluation protocol.Ninety (98%) patients are alive after ame-
dian follow-up of 77 months (range 38–167). Evaluation of the 38
female patients (median age at transplant 33, range 9–60 years) in-
cluded annual gynecological examination. Thirty five received
a fractionated total body irradiation (TBI) (12–13.6 Gy) based mye-
loablative SCT and 3 received a non-TBI non-myeloablative SCT.
Acute graft versus host disease (GVHD) (grade II-IV) occurred in 9
(24%) patients and chronic GVHD in 34 (89%), extensive in 10
(26%). Six (16%) patients received immunosuppressive therapy
(IST) for chronic GVHD beyond 3 years from SCT. Thirty-five
(92%) adult patients had annual cervical smear examinations, 14
(40%) were abnormal. High grade dysplasia was seen in 8 (23%),
low grade lesions in 4 (11%) and 2 patients had atypical cells of un-
certain significance. Median time to an abnormal smear was 51
months (17–153) and median age of these 12 patients was 42 years
(range 19–62). Extensive chronic GVHD requiring prolonged
IST was the only factor associated with an increased risk of cervical
dysplasia (p 5 0.028). Our data shows that cervical dysplasia (often
high grade) is common after allo-SCT. These patients may be at in-
creased risk of developing invasive cervical cancer. Patients requir-
ing prolonged immunosuppression for chronic GVHD treatment
may be especially at risk for all forms of HPV-related malignancy.
Aggressive screening and preventive strategies with HPV vaccine
appear warranted.51
NATIONAL INSTITUTE OF HEALTH’S RECOMMENDATION FOR ASSESS-
ING LUNG FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION PREDICTS MORTALITY RISK
Walter, E.C.1,2, Orozco-Levi, M.3, Ramirez-Sarmiento, A.3,
Chien, J.W.1,2. 1University of Washington School of Medicine, Seattle,
WA; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Hospital
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Background: The NIH recently published a consensus state-
ment that recommends monitoring FEV1 and DLCO to evaluate
changes in lung function after allogeneic hematopoietic cell trans-
plantation (aHCT). Although this recommendation was based
upon previous analysis of pre-transplant pulmonary function tests
(PFT), their clinical validity and utility have not yet been examined.
We conducted an analysis to determine whether FEV1 and DLCO
are the most informative measurements for post-transplant lung
function change by assessing their relationship with mortality after
aHCT.Methods:Weperformed a retrospective review of 1929 pa-
tients who underwent aHCT from 1993–2002 and received PFTs
within 60–100 days after transplant. Post-transplant FEV1, FVC,
TLC, and DLCO were categorized as ./580, 70–80, 60–70 and
\ 60% predicted. FEV1/FVC ratio was categorized as ./5 0.7
and\ 0.7. Per NIH recommendations lung function score (LFS,
range 2–12) was calculated using FEV1 and DLCO. LFS was
then categorized from 0–3 (category O 5 LFS 2; category 1 5
LFS 3–5; category 25LFS 6–9; category 35LFS 10–12).Results:
Two year all cause mortality after aHCTwas 32%. Univariate anal-ysis showed a stepwise increase in mortality with each categorical
decrease in FEV1, FVC, TLC, and DLCO. There was no signifi-
cant relationship between FEV1/FVC ratio and mortality. Mortal-
ity increased with increasing LFS (category 1 hazard ratio [HR],
1.50; category 2 HR, 2.86; category 3 HR, 5.64; p\0.001; c-statis-
tic 0.6). The LFS appeared to have a stronger association with mor-
tality than did any individual lung function parameter. However,
the LFS was not uniformly distributed with a significantly lower
number of patients in LFS categories 2 and 3 (mean LFS score
3.3). Summary: These results suggest that decreased lung function
by day 100 following aHCT is a risk factor for mortality. An ele-
vated LFS is associated with an increased risk of mortality. The
LFS may serve as a mechanism to grade severity of decreased
lung function in future clinical trials. However, the scoring system
may need to be altered to improve discrimination as it is currently
weighted towards patients with normal to near normal lung func-
tion. Abbreviations: FEV15Forced expiratory volume in 1 sec,
FVC5Forced vital capacity, TLC5Total lung capacity,
DLCO5Diffusion capacity of carbon monoxide.
Two year mortality as a function of post-transplant lung function
parameters and lung function score categories
Lung function
parameters Died (%) HR (95% CI) p-valueFEV1 (%) (n 5 1929)
.80 388/1397 (28) Referent
70–80 112/310 (36) 1.39 (1.13–1.72) 0.002
60–70 66/144 (46) 1.96 (1.51–2.55) \0.001
\60 56/78 (72) 3.84 (2.90–5.09) \0.001FVC (%) (n 5 1929)
.80 429/1545 (28) Referent
70–80 103/236 (44) 1.81 (1.46–2.25) \0.001
60–70 55/101 (54) 2.44 (1.85–3.24) \0.001
\60 35/47 (74) 4.19 (2.97–5.92) \0.001TLC (%) (n 5 1904)
.80 475/1644 (29) Referent
70–80 86/187 (46) 1.87 (1.49–2.36) \0.001
60–70 33/56 (59) 2.64 (1.85–3.76) \0.001
\60 13/17 (76) 4.35 (2.51–7.55) \0.001DLCO (%) (n 5 1893)
.80 245/995 (25) Referent
70–80 127/408 (31) 1.28 (1.03–1.59) 0.023
60–70 142/311 (46) 2.12 (1.72–2.60) \0.001
\60 91/179 (51) 2.50 (1.96–3.18) \0.001LFS category (n 5 1893)
0 (LFS 2) 205/849 (24) Referent
1 (LFS 3–5) 291/851 (34) 1.50 (1.25–1.79) \0.001
2 (LFS 6–9) 96/178 (54) 2.86 (2.25–3.65) \0.001
3 (LFS 10–12) 13/15 (87) 5.64 (3.22–9.88) \0.001Definition of abbreviations: CI5 confidence interval; LFS5 Lung
function score. Data was not available for all lung function
parameters for all patients.LEUKEMIA52
A SINGLE DOSE OF GEMTUZUMAB-OZOGAMICIN (GO) IN CONSOLIDA-
TION PRIOR TO AUTOLOGOUS TRANSPLANT FOR YOUNGER PATIENTS
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